

Clinical trials of ibopamine

TrialResults-center www.trialresultscenter.org

1 heart failure

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|---------------------------------|
| ibopamine vs placebo | | | |
| PRIME II , 1997 n=953/953 follow-up: mean 11.4 months | oral ibopamine 100 mg three times daily versus placebo | patients with heart failure NYHA III-IV | Parallel groups double blind |

More details and results :

- phosphodiesterase III inhibitors for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q117>

References

PRIME II, 1997:

Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancica G, Skene AM
Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7 [[9100622](#)]